Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Conflict of interest

All authors have completed the conflict-of-interest disclosure in accordance with the requirements of the International Journal of Clinical Oncology and the policy of the Japanese Society of Medical Oncology. The disclosures were reviewed by the society’s conflict-of-interest committee to ensure appropriate participation in the guideline development process. The following potential conflicts of interest are disclosed: A.O. reports honoraria from Chugai Pharmaceutical Co., Ltd. and Eisai Co., Ltd. H.Y. reports honoraria from AstraZeneca K.K., Kyorin Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., MSD K.K., Pfizer Japan Inc., Kyowa Kirin Co., Ltd., Amgen K.K., GlaxoSmithKline K.K., Daiichi Sankyo Co., Ltd., Teijin Healthcare Limited, Sanofi K.K., Insmed Incorporated, Bristol-Myers Squibb K.K., Nippon Kayaku Co., Ltd., and Life Technologies Japan Ltd.; fees for promotional materials from Chugai Pharmaceutical Co., Ltd. and bioMérieux Japan Ltd.; and research funding from AstraZeneca K.K., Kyorin Pharmaceutical Co., Ltd., CES Decartes, and Ono Pharmaceutical Co., Ltd. F.N. reports honoraria from Taiho Pharmaceutical, Ono Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Yakult Honsha, Janssen, Merck, and Daiichi Sankyo; and research funding from Ono Pharmaceutical, OncoTherapy Science, Merck Serono, Zeria Pharmaceutical, Eli Lilly, Takeda Pharmaceutical, Chugai Pharmaceutical, Yakult Honsha, Sumitomo Pharma, Daiichi Sankyo, Shionogi, J-Pharma, Bristol-Myers Squibb, Kyowa Kirin, Mochida Pharmaceutical, Astellas Pharma, Bayer, MSD, Eisai, NanoCarrier, Janssen, Baxalta/Shire, and Novartis. A.M. reports honoraria from Chugai Pharmaceutical and Taiho Pharmaceutical. The other authors declare no conflicts of interest.